1-833-209-3704
Compounded GLP-1s Are Ending in the U.S.: What’s Changing—and How Americans Turn to Canada for Cheaper GLP-1s
Compounded GLP-1s Are Ending in the U.S.: What’s Changing—and How Americans Turn to Canada for Cheaper GLP-1s
For the past couple of years, many Americans relied on compounded GLP-1 medications as a cost workaround—especially when brand name options were hard to find or too expensive. Now the landscape is changing quickly. Patients are hearing that compounded GLP-1s are “going away,” clinics are updating their policies, and people are trying to figure out what comes next without losing progress.
This post explains what’s happening in plain language, why compounded GLP-1s and regulated generics are two different things, and why more Americans are turning to buying from Canada for cheaper GLP-1 options like Mounjaro/Zepbound and Ozempic/Wegovy—including generic semaglutide now approved in Canada.
What does “compounded GLP-1” mean?
A compounded medication is typically prepared by a compounding pharmacy rather than manufactured as a mass-produced, standardized commercial product. With GLP-1s, compounded products have often been offered as an alternative when patients couldn’t access or afford brand name medications.
The key patient point is that compounded products can vary more than people realize:
- formulation and concentration can differ between pharmacies
- labeling and dosing formats can be less standardized
- consistency from batch to batch may not match a large-scale manufacturer product
Some patients had a good experience. Others had uneven results. But either way, compounding became a “pressure relief valve” during shortage and affordability crunches.
Why are compounded GLP-1s ending in the U.S.?
This shift is largely tied to federal policy around drug shortages and when compounding pharmacies can produce “essentially copies” of brand name products.
The FDA has issued public updates explaining that as national GLP-1 supply stabilizes, it is clarifying policies for compounders and tightening what can be compounded as “copy” products.
Two key milestones that changed the compounding landscape:
- Tirzepatide injection shortage resolved: The FDA determined (and reaffirmed) that the tirzepatide injection product shortage is resolved (the reevaluation decision is dated December 19, 2024).
- Semaglutide injection shortage resolved: The FDA issued a declaratory order stating semaglutide injection product shortage is resolved (dated February 21, 2025).
What this means in real life: once the shortage-based exception closes, widespread compounding of “copy” GLP-1s becomes much harder to support under the FDA’s framework. The net effect for patients is fewer compounded options and more uncertainty in availability.
Compounded semaglutide and generic semaglutide are not the same thing
This is where a lot of online confusion happens.
Compounded semaglutide:
- prepared by a compounding pharmacy
- can vary by formulation and sourcing
- often discussed as a workaround during shortages
- a regulated product made by a manufacturer
- authorized through national regulatory review as a generic equivalent to a brand name reference product
- standardized dosing formats and labeling
So when compounded supply tightens in the U.S., the best “next step” for many patients isn’t another compounded workaround—it’s finding a stable, regulated option they can actually stay on.
Why Canada is becoming the go-to alternative for cheaper GLP-1s
Canada has become central to this conversation for two reasons:
Generic semaglutide is now authorized in Canada. Health Canada announced it authorized the first generic semaglutide injection on April 28, 2026, and noted it is reviewing additional submissions.
Brand name GLP-1s in Canada can be more predictable in pricing. Reuters reported that Eli Lilly reduced prices in Canada for Mounjaro and Zepbound, citing new Canadian pharmacy pricing effective late December 2025.
That combination—generic semaglutide availability + more stable brand name pricing dynamics—is why Americans searching “cheap medications from Canada” increasingly land on GLP-1 topics.
What are the Canada options Americans ask about most?
Here are the GLP-1 options most commonly discussed when Americans look north for affordability:
- Generic semaglutide injection (Canada)
A regulated generic option that is comparable to brand name semaglutide injection products in the sense that it’s a standardized manufacturer-made product (not compounded). - Brand name semaglutide options (Ozempic/Wegovy)
Patients often compare their current Ozempic or Wegovy prescriptions and ask whether they can move to a generic semaglutide option if appropriate for their clinician’s plan. - Tirzepatide options (Mounjaro / Zepbound)
Patients who did well on tirzepatide but can’t sustain U.S. pricing often compare Canadian routes. Reuters also reported Canadian price reductions for Mounjaro/Zepbound.
If you’ve been relying on compounded GLP-1s, this is the practical fork in the road: regulated generic semaglutide in Canada, or brand name options with more stable pricing routes.
Can patients switch from their current prescription to a Canada option?
In many cases, yes—patients usually just need their prescriber’s prescription written clearly for the product and dose plan they’re following.
What typically needs to be clear:
- medication name and form (example: semaglutide injection vs tirzepatide)
- weekly dose and titration plan
- quantity (30 vs 90 days, where appropriate)
- refills (if the prescriber is comfortable)
A lot of patients also ask if a current Ozempic or Wegovy prescription can be “converted” to generic semaglutide wording (where clinically appropriate). This is often a paperwork clarity issue, not a clinical mystery.
What about patients who can’t afford Mounjaro?
This is one of the most common patient scenarios right now.
Tirzepatide (Mounjaro/Zepbound) can be extremely effective, but cost is a real barrier. For many patients, semaglutide is still a strong option for:
- type 2 diabetes management
- weight loss support under a prescriber-guided plan
If Mounjaro is out of budget, switching to a semaglutide plan is often better than stopping GLP-1 therapy entirely—especially if generic semaglutide pricing in Canada makes consistency realistic.
Microdosing and stretching supply: why affordability changes the strategy
When patients have predictable access, they’re less likely to “stretch doses” out of desperation. But some clinicians do use slower titration or lower weekly doses intentionally for tolerability.
If your prescriber is using a slower approach, more affordable options can:
- reduce stop-start treatment cycles
- make long-term adherence easier
- support steady lifestyle routines (protein-forward meals, hydration, activity) that work best when therapy is consistent
Any microdosing strategy should be prescriber-guided, but affordability often determines whether patients can follow the plan properly.
Cost & access: where Over the Border Meds fits
Americans are always looking for cheaper ways to access medications—especially when compounded GLP-1 options are disappearing and brand pricing in the U.S. feels impossible.
Over the Border Meds helps patients access brand name medications and comparable options from Canada at a fraction of the cost many patients face in the U.S., depending on availability and prescription details. Patients can contact the team for:
- current pricing on Canadian GLP-1 options (including generic semaglutide when available)
- help translating an Ozempic/Wegovy prescription to generic semaglutide wording (when appropriate)
- refill timing guidance and general questions
FAQ: What you need to know
Are compounded GLP-1s and generic GLP-1s the same thing?
No. Compounded products are prepared by a compounding pharmacy. Generics are standardized manufacturer products authorized through regulatory review.
Why are compounded semaglutide and compounded tirzepatide becoming harder to find in the U.S.?
The FDA determined the tirzepatide injection shortage and semaglutide injection shortage are resolved, and it has clarified compounding policies as supply stabilizes.
Is generic semaglutide available in Canada now?
Yes—Health Canada announced authorization of the first generic semaglutide injection on April 28, 2026.